Robert Gould, Fulcrum Therapeutics CEO

Ful­crum stum­bles in PhII of old GSK drug, send­ing shares tum­bling

In­vestors are sell­ing off shares of Ful­crum Ther­a­peu­tics $FULC af­ter their lead drug failed in a Phase II tri­al.

The com­pa­ny, found­ed three years ago on new re­search tech­niques such as CRISPR screen­ing, iso­lat­ed a gene called DUX4 they be­lieved to have a cen­tral role in fa­cioscapu­lo­humer­al mus­cu­lar dy­s­tro­phy, where pa­tients’ mus­cle dies and is re­placed by fat. And to tar­get it, they li­censed a Glax­o­SmithK­line drug that had failed as a car­dio drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.